The Efficacy and Safety of Evogliptin for Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Sep 5

PMID 36060938

Authors

Qizhi Tang

Weiyu Pan

Liangyue Peng

Affiliations

Soon will be listed here.

Abstract

Introduction: The dipeptidyl peptidase-4 inhibitor (DPP-4i) drugs, such as evogliptin, as the second-line drugs for type 2 diabetes mellitus (T2DM) treatment have been reported to facilitate insulin secretion by reducing glucagon and inhibiting glucagon like peptides. With a vague consensus, the advantageous and non-inferior effects of evogliptin relative to other DPP-4i drugs were recently demonstrated on hemoglobin A1c (HbA1c) levels and overall adverse events in T2DM patients. Thus, the aim was to evaluate the overall influence of evogliptin on HbA1c levels and the adverse events in T2DM patients compared to sitagliptin and linagliptin.

Methods: Complying with PRISMA guidelines, we conducted a systematic literature search in databases and a meta-analysis. Data about HbA1c levels and the adverse events of T2DM patients were collected and analyzed.

Results: From 1,397 studies, we found five matched studies involving 845 subjects (mean age: 54.7 ± 3 years). The meta-analysis revealed that evogliptin was non-inferior to sitagliptin/linagliptin with a mean difference of 0.062 (95% CI: -0.092 to 0.215. I: 0%. = 0.431) regarding the HbA1c level reduction, and the risk ratio was -0.006 (95% CI: -0.272 to 0.260. I: 1.7%. = 0.966) regarding the adverse effects, indicating no significant difference between evogliptin and linagliptin or sitagliptin in affecting the HbA1c level and adverse effects.

Conclusion: The study provides preliminary evidence regarding the similarity in the efficacy of evogliptin compared to other DPP-4i drugs, including sitagliptin and linagliptin, for managing HbA1c levels and adverse events.

Citing Articles

Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: Harnessing the power of nanotheranostics.

Nag S, Mitra O, Maturi B, Kaur S, Saini A, Nama M Asian J Pharm Sci. 2024; 19(3):100927.

PMID: 38948399 PMC: 11214300. DOI: 10.1016/j.ajps.2024.100927.

Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update.

Kolaric T, Kuna L, covic M, Roguljic H, Matic A, Sikora R Curr Issues Mol Biol. 2023; 45(5):4246-4260.

PMID: 37232739 PMC: 10216970. DOI: 10.3390/cimb45050270.

References

Ma M, Liang S, Zhu J, Dai M, Jia Z, Huang H . The Efficacy and Safety of Bivalirudin Versus Heparin in the Anticoagulation Therapy of Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. Front Pharmacol. 2022; 13:771563. PMC: 9048024. DOI: 10.3389/fphar.2022.771563. View

Shi L, Lin L . The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore). 2019; 98(23):e15987. PMC: 6571372. DOI: 10.1097/MD.0000000000015987. View

Magliano D, Sacre J, Harding J, Gregg E, Zimmet P, Shaw J . Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. Nat Rev Endocrinol. 2020; 16(6):321-331. DOI: 10.1038/s41574-020-0334-z. View

Ajmani A, Agrawal A, Prasad B, Basu I, Shembalkar J, Manikanth N . Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study. Diabetes Res Clin Pract. 2019; 157:107860. DOI: 10.1016/j.diabres.2019.107860. View

Gu N, Park M, Kim T, Bahng M, Lim K, Cho S . Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel Ther. 2014; 8:1709-21. PMC: 4199987. DOI: 10.2147/DDDT.S65678. View

Deacon C, Lebovitz H . Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2015; 18(4):333-47. DOI: 10.1111/dom.12610. View

Scheen A . Pathophysiology of type 2 diabetes. Acta Clin Belg. 2004; 58(6):335-41. DOI: 10.1179/acb.2003.58.6.001. View

Yitbarek G, Ayehu G, Asnakew S, Chanie E, Bayih W, Feleke D . Undiagnosed diabetes mellitus and associated factors among adults in Ethiopia: a systematic review and meta-analysis. Sci Rep. 2021; 11(1):24231. PMC: 8688487. DOI: 10.1038/s41598-021-03669-y. View

Lee J, Noh S, Lim S, Kim B . Plant Extracts for Type 2 Diabetes: From Traditional Medicine to Modern Drug Discovery. Antioxidants (Basel). 2021; 10(1). PMC: 7827314. DOI: 10.3390/antiox10010081. View

10.

Kim G, Lim S, Kwon H, Park I, Ahn K, Park C . Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study). Diabetes Obes Metab. 2020; 22(9):1527-1536. PMC: 7496811. DOI: 10.1111/dom.14061. View

11.

Hales C, Barker D . Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. 1992. Int J Epidemiol. 2013; 42(5):1215-22. DOI: 10.1093/ije/dyt133. View

12.

Misra A, Ganda O . Migration and its impact on adiposity and type 2 diabetes. Nutrition. 2007; 23(9):696-708. DOI: 10.1016/j.nut.2007.06.008. View

13.

Park J, Park S, Yoon K, Kim S, Ahn K, Lee J . Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise. Diabetes Obes Metab. 2017; 19(12):1681-1687. PMC: 5697645. DOI: 10.1111/dom.12987. View

14.

Luo H, Li D, Gao F, Hong P, Feng W . A meta-analysis of neonatal outcomes in pregnant women with immune thrombocytopenic purpura. J Obstet Gynaecol Res. 2021; 47(9):2941-2953. DOI: 10.1111/jog.14890. View

15.

Henriksen E, Diamond-Stanic M, Marchionne E . Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med. 2010; 51(5):993-9. PMC: 3071882. DOI: 10.1016/j.freeradbiomed.2010.12.005. View

16.

Awad S, A Toumi A, A Al-Mutawaa K, Alyafei S, A Ijaz M, A H Khalifa S . Type 2 diabetes epidemic and key risk factors in Qatar: a mathematical modeling analysis. BMJ Open Diabetes Res Care. 2022; 10(2). PMC: 9021773. DOI: 10.1136/bmjdrc-2021-002704. View

17.

Cercato C, Felicio J, Russo L, Borges J, Salles J, Muskat P . Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study. Diabetol Metab Syndr. 2020; 11:107. PMC: 6923891. DOI: 10.1186/s13098-019-0505-z. View

18.

Shah B, Modi P, Trivedi P . Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors. Curr Med Chem. 2020; 28(18):3595-3621. DOI: 10.2174/0929867327666201012153255. View

19.

Hong S, Park C, Hwang D, Han K, Lee C, Chung C . Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension. Diabetes Obes Metab. 2017; 19(5):654-663. PMC: 5412933. DOI: 10.1111/dom.12870. View